Milan, 17 April 2020 – Falck Renewables S.p.A. supports two medical research projects conducted at the Università degli Studi of Milan (University of Milan) and aimed at combating the pathological effects of Covid-19.

A first study, coordinated by Prof. Gian Vincenzo Zuccotti
[1], focuses on “Research of new therapeutic targets and diagnostic biomarkers for Covid-19” and is aimed to understand the mechanisms of resistance to infection and disease progression, explaining its epidemiological peculiarities, up to the identification of new molecules to be used in the clinical setting. The research will be carried out at the “Centro di Ricerca Pediatrica Romeo ed Enrica Invernizzi” of the Department of Biomedical Sciences and Clinics “Luigi Sacco” of the University of Milan. Preliminary results are expected already in the next three months.

The second research, coordinated by Prof. Massimo Galli
[2] and conducted at the Laboratory of Infectious Diseases of the same Department, will deal with the molecular mapping and in vitro pharmacological response of the SARS-CoV-2 epidemic in Northern Italy. Falck Renewables is co-financing this study by participating in the fundraising campaign organized by Fondazione Sodalitas.


We strongly believe in these activities – says Toni Volpe, Chief Executive Officer of Falck Renewables – which aim to offer new weapons in the fight against the serious health crisis we are experiencing. We believe it is a strong ethical and social duty to support research, looking for a better and more sustainable future for everyone“.


The contribution of Falck Renewables – granted as donations and amounting to Euro 200 thousand – is part of a wider support programme that Falck Renewables S.p.A., Falck S.p.A and Fondazione Falck have been providing to organizations and healthcare institutions in this difficult time of health and social emergency. 




[1] Prof. Gian Vincenzo Zuccotti is the Scientific Coordinator of the Centro Invernizzi and Chairman of the Management Board of the Faculty of Medicine and Surgery, University of Milan, and Director of the Pediatric Department of the V. Buzzi ASST Fatebenefratelli Sacco Hospital. 


[2] Prof. Massimo Galli is director of the Laboratory of Infectious Diseases of the Department of Biomedical Sciences and Clinics Luigi Sacco, University of Milan.


Falck Renewables S.p.A., listed on the Italian stock exchange in the STAR segment (“FKR.MI”) and included in the FTSE Italia Mid Cap Index, develops, designs, builds and manages power production plants from renewable sources, with an installed capacity of 1,133 MW (1,096.5 MW according to the IFRS 11 reclassification) in the United Kingdom, Italy, United States, Spain, France, Norway and Sweden, using wind power, solar power, WtE and biomass technologies. The Group is a global player in the renewable energy technical advisory and asset management services business, through its wholly owned subsidiary Vector Cuatro, providing asset management services to clients accounting for approximately 2,500 MW of installed capacity and with experience in more than 40 countries.




Falck Renewables

Giorgio BOTTA – Investor Relations – Tel. +39 02 2433 3338

Alessandra RUZZU – Media Relations – Tel. + 39 02 2433 2360

SEC Newgate S.p.A

Daniele Pinosa, Fabio Leoni, Fabio Santilio – Tel. +39 02 6249991

CDR Communication

Vincenza Colucci – Tel. +39 335 6909547

Alternative Language Versions